Burling Wealth Partners LLC Purchases New Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Burling Wealth Partners LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 976 shares of the medical research company's stock, valued at approximately $508,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. J. Stern & Co. LLP increased its stake in Thermo Fisher Scientific by 5.9% in the fourth quarter. J. Stern & Co. LLP now owns 57,538 shares of the medical research company's stock valued at $29,933,000 after acquiring an additional 3,198 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its position in Thermo Fisher Scientific by 9.1% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 390,315 shares of the medical research company's stock valued at $203,054,000 after acquiring an additional 32,591 shares during the last quarter. Coppell Advisory Solutions LLC lifted its stake in Thermo Fisher Scientific by 21.6% in the fourth quarter. Coppell Advisory Solutions LLC now owns 276 shares of the medical research company's stock worth $144,000 after purchasing an additional 49 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in Thermo Fisher Scientific by 86.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after acquiring an additional 1,433,444 shares during the period. Finally, Pinebridge Investments L.P. increased its holdings in Thermo Fisher Scientific by 26.6% during the 4th quarter. Pinebridge Investments L.P. now owns 125,815 shares of the medical research company's stock valued at $65,453,000 after purchasing an additional 26,466 shares during the period. Institutional investors own 89.23% of the company's stock.

Analysts Set New Price Targets

TMO has been the subject of a number of analyst reports. Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Barclays decreased their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Raymond James reaffirmed an "outperform" rating and set a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Finally, StockNews.com downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Five analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average price target of $610.27.

Thermo Fisher Scientific Stock Down 0.0 %

Shares of TMO stock traded down $0.08 during trading hours on Wednesday, reaching $427.45. 647,468 shares of the company's stock were exchanged, compared to its average volume of 1,748,566. The stock's 50 day moving average is $482.87 and its 200-day moving average is $524.80. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a fifty-two week low of $409.85 and a fifty-two week high of $627.88. The company has a market cap of $161.36 billion, a price-to-earnings ratio of 25.86, a P/E/G ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm's quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the firm posted $5.11 earnings per share. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were paid a $0.43 dividend. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific's payout ratio is currently 10.09%.

Insider Activity

In other news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares of the company's stock, valued at $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 in the last ninety days. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.